Cargando…

Advances in immunotherapy for cervical cancer

Cervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-estab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grau-Bejar, Juan Francisco, Garcia-Duran, Carmen, Garcia-Illescas, David, Mirallas, Oriol, Oaknin, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Immunotherapy in Gynecological Cancers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052578/ https://www.ncbi.nlm.nih.gov/pubmed/37007635 http://dx.doi.org/10.1177/17588359231163836

Ejemplares similares

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials
por: Eskander, Ramez N., et al.
Publicado: (2021)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

Cell therapies in ovarian cancer
por: Sarivalasis, Apostolos, et al.
Publicado: (2021)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer
por: Doo, David W., et al.
Publicado: (2020)

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
por: Lee, Elizabeth K., et al.
Publicado: (2020)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Global research trends on immunotherapy in cancer: A bibliometric analysis
por: Yao, Zhichao, et al.
Publicado: (2023)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

The Impact of High-Dose-Rate Brachytherapy: Measuring Clinical Outcomes in the Primary Treatment of Cervical Cancer
por: Song, Jiheon, et al.
Publicado: (2020)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
por: DeBenedette, Mark, et al.
Publicado: (2023)

Identification of key immune cell-related genes involved in tumorigenesis and prognosis of cervical squamous cell carcinoma
por: Yan, Chunxiao, et al.
Publicado: (2023)

Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023)

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis
por: Zhao, Juan, et al.
Publicado: (2023)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Bibliometric analysis of RNA vaccines for cancer
por: Yang, Xue, et al.
Publicado: (2023)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
por: Johannet, Paul, et al.
Publicado: (2020)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
por: Deng, Jia-Yi, et al.
Publicado: (2023)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
por: Odeny, Thomas A, et al.
Publicado: (2022)

Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration
por: Sultan, Hussein, et al.
Publicado: (2020)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

A combined clinical and genetic model for predicting risk of ovarian cancer
por: Dite, Gillian S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sh1qq85qqleoncg5u3ogkhhedk